DYSKINESIA

 

Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia.                                                    (abst – 1985)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=142

 

The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease (PD).                                                                 (abst – 1998)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=153

 

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. (abst – 2001)                                        http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=54

 

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. (abst – 2001)                                        http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=54

 

Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia.                                                                      (abst – 2002)  http://www.ncbi.nlm.nih.gov/pubmed/12421641

 

Medical Marijuana and Tardive Dyskinesia (TD)                         (news – 2009)

https://www.marijuanadoctors.com/content/ailments/view/124?ailment=tardive-dyskinesia-td-

 

Tardive Dystonia and the Use of Cannabis.                    (abst – 2010)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=303

 

Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys.                                                                 (abst – 2011)   http://www.ncbi.nlm.nih.gov/pubmed/21029743

 

Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia (abst – 2011)                                         http://www.ncbi.nlm.nih.gov/pubmed/21266946

 

The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.                                                 (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/20888328/abstract/The_effects_of_cannabinoid_dr   ugs_on_abnormal_involuntary_movements_in_dyskinetic_and_non_dyskinetic_6_hydroxydopamine_lesio   ned_rats_

 

The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.                                                             (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22192465

Share a link for